If a patient develops a deep vein thrombosis while on therapeutic apixaban (Eliquis), should they undergo a hypercoagulable workup?

Hypercoagulable Workup for Breakthrough DVT on Apixaban

Yes, a patient who develops DVT while on therapeutic apixaban should undergo targeted evaluation for underlying causes, though a comprehensive thrombophilia panel is not routinely indicated for all patients.

Initial Assessment Priority

When a patient develops breakthrough VTE on apixaban, your first steps should focus on three critical assessments 1, 2:

1. Confirm true recurrence - Verify this is genuinely new thrombosis, not residual clot or misdiagnosis
2. Verify medication compliance - Document actual adherence, not just patient report
3. Evaluate for malignancy - Active cancer is the most common culprit for anticoagulation failure

Specific Workup Recommendations

Immediate Evaluation Required

• Cancer screening if not already diagnosed - This is the single most important investigation, as occult malignancy is a leading cause of breakthrough thrombosis 1, 2
• Medication review for drug interactions - Check for P-glycoprotein inhibitors or CYP3A4 inducers that could affect apixaban levels 3
• Renal function assessment - Apixaban dosing depends on creatinine clearance; deteriorating renal function may lead to subtherapeutic levels 3

Selective Thrombophilia Testing

Consider testing for antiphospholipid syndrome specifically if the patient has 4, 2:

• Young age (<50 years)
• Arterial thrombosis in addition to venous events
• History of pregnancy morbidity
• Recurrent thrombosis at unusual sites

The evidence shows antiphospholipid syndrome may require LMWH or warfarin rather than DOACs 5. Testing should include anticardiolipin antibodies (IgG and IgM) and lupus anticoagulant, repeated 6 weeks apart for confirmation.

Routine thrombophilia panels (Factor V Leiden, prothrombin G20210A, protein C/S deficiency) are generally NOT recommended for breakthrough VTE on anticoagulation because:

• These results rarely change management
• The patient already requires indefinite anticoagulation
• The association with arterial/venous thrombosis is weak 4

Management Algorithm

Immediate Anticoagulation Change

Switch from apixaban to LMWH temporarily 1, 2. The 2016 CHEST guidelines specifically recommend this approach for recurrent VTE on DOACs:

• Start therapeutic LMWH (enoxaparin 1 mg/kg subcutaneously every 12 hours or dalteparin 200 units/kg daily)
• Continue LMWH for at least 1 month
• If compliance and dosing were appropriate, consider increasing LMWH dose by 25-33% 1

Special Considerations

If antiphospholipid syndrome is confirmed: Transition to warfarin (INR 2.0-3.0) rather than returning to a DOAC, as DOACs have shown inferior efficacy in this population 4, 5.

If active malignancy is present: Continue LMWH indefinitely or consider switching to a different oral factor Xa inhibitor (rivaroxaban or edoxaban) rather than returning to apixaban 6, 2.

If heparin-induced thrombocytopenia (HIT) is suspected: This is critical if the patient recently received UFH or LMWH. Check platelet count and HIT antibodies immediately. If HIT is confirmed, use a non-heparin anticoagulant 2.

Common Pitfalls to Avoid

• Don't assume compliance without verification - Use pharmacy refill records, not just patient report
• Don't continue the same DOAC at the same dose - This has failed once already
• Don't order extensive thrombophilia panels reflexively - Focus on actionable diagnoses (cancer, antiphospholipid syndrome)
• Don't forget to check for gastric/GI malignancy - Particularly relevant given apixaban use, as GI tumors increase bleeding risk with DOACs 6

Duration of Alternative Anticoagulation

After switching to LMWH, reassess at 1 month 2:

• If underlying cause identified (cancer, antiphospholipid syndrome): Treat accordingly with appropriate long-term anticoagulation
• If no cause found and patient stable: Consider switching to oral anticoagulation, but not back to apixaban - use warfarin or a different DOAC
• Continue indefinite anticoagulation regardless, as breakthrough VTE indicates high recurrence risk

The key principle: Breakthrough thrombosis on therapeutic anticoagulation is unusual and demands investigation for underlying pathology, but the workup should be targeted rather than exhaustive 1, 2.